| ISIN | LU2050612402 |
|---|---|
| Valor Number | |
| Bloomberg Global ID | |
| Fund Name | JPMorgan Funds – Thematics - Genetic Therapies A (acc)-USD |
| Fund Provider |
J.P. Morgan Bank Luxembourg S.A.
6, route de Trèves L-2633, Senningerberg Grand Duchy of Luxembourg |
| Fund Provider | J.P. Morgan Bank Luxembourg S.A. |
| Representative in Switzerland |
JPMorgan Asset Management (Switzerland) LLC Genève Phone: +41 22 744 11 11 |
| Distributor(s) |
JP Morgan Asset Management (Europe) Sàrl Senningerberg Phone: +352 34 10 1 |
| Asset Class | Equities |
| EFC Category | |
| Distribution Policy | Accumulation |
| Home Country | Luxembourg |
| Issuing Condition | Combination of issuing commission charged by the fund management company and transaction fee charged by the fund |
| Redemption Condition | Combination of redemption commission charged by the fund management company and transaction fee charged by the fund |
| Investment Strategy *** | To achieve a return by investing in companies with exposure to the theme of genetic therapies, globally. |
| Peculiarities |
| Current Price * | 106.45 USD | 20.11.2025 |
|---|---|---|
| Previous Price * | 104.67 USD | 19.11.2025 |
| 52 Week High * | 107.89 USD | 16.10.2025 |
| 52 Week Low * | 72.17 USD | 09.04.2025 |
| NAV * | 106.45 USD | 20.11.2025 |
| Issue Price * | ||
| Redemption Price * | ||
| Closing Price * | ||
| Indicative Minimum Price | ||
| Fund Assets *** | 397,375,109 | |
| Unit/Share Assets *** | 108,135,260 | |
| Trading Information SIX | ||
| YTD Performance | +18.05% |
31.12.2024 - 20.11.2025
31.12.2024 20.11.2025 |
|---|---|---|
| YTD Performance (in CHF) | +4.76% |
31.12.2024 - 20.11.2025
31.12.2024 20.11.2025 |
| 1 month | -0.20% |
20.10.2025 - 20.11.2025
20.10.2025 20.11.2025 |
| 3 months | +16.75% |
20.08.2025 - 20.11.2025
20.08.2025 20.11.2025 |
| 6 months | +30.74% |
20.05.2025 - 20.11.2025
20.05.2025 20.11.2025 |
| 1 year | +15.48% |
20.11.2024 - 20.11.2025
20.11.2024 20.11.2025 |
| 2 years | +14.11% |
20.11.2023 - 20.11.2025
20.11.2023 20.11.2025 |
| 3 years | -3.37% |
21.11.2022 - 20.11.2025
21.11.2022 20.11.2025 |
| 5 years | -29.44% |
20.11.2020 - 20.11.2025
20.11.2020 20.11.2025 |
| Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ADDI Date | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Avidity Biosciences Inc Ordinary Shares | 3.76% | |
|---|---|---|
| uniQure NV | 3.44% | |
| Ionis Pharmaceuticals Inc | 3.35% | |
| PTC Therapeutics Inc | 3.27% | |
| CRISPR Therapeutics AG | 2.99% | |
| Gilead Sciences Inc | 2.82% | |
| Novartis AG Registered Shares | 2.78% | |
| Alnylam Pharmaceuticals Inc | 2.78% | |
| Krystal Biotech Inc | 2.77% | |
| Wuxi AppTec Co Ltd | 2.66% | |
| Last data update | 31.10.2025 | |
| TER *** | 0.95% |
|---|---|
| TER date *** | 30.06.2025 |
| Performance Fee *** | |
| PTR | |
| Max. Management Fee *** | 0.72% |
| Ongoing Charges *** | 0.95% |
|
SRRI ***
|
|
| SRRI date *** | 31.10.2025 |